Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 115

1.

Comment on 'Sustained discontinuation of infliximab with a raising-dose strategy after obtaining remission in patients with rheumatoid arthritis: the RRRR study, a randomised controlled trial' by Tanaka et al.

Berkhout LC, l'Ami MJ, Wolbink GJ, Rispens T.

Ann Rheum Dis. 2019 Nov 19. pii: annrheumdis-2019-216557. doi: 10.1136/annrheumdis-2019-216557. [Epub ahead of print] No abstract available.

PMID:
31744825
2.

The effect of methotrexate on tumour necrosis factor concentrations in etanercept-treated rheumatoid arthritis patients.

Berkhout LC, l'Ami MJ, Krieckaert CLM, Vogelzang EH, Kos D, Nurmohamed MT, Wolbink GJ, Rispens T.

Rheumatology (Oxford). 2019 Nov 6. pii: kez513. doi: 10.1093/rheumatology/kez513. [Epub ahead of print]

PMID:
31691828
3.

The effect of certolizumab drug concentration and anti-drug antibodies on TNF neutralisation.

Berkhout LC, Vogelzang EH, Hart MM, Loeff FC, Dijk L, Derksen NIL, Wieringa R, van Leeuwen WA, Krieckaert CLM, de Vries A, Nurmohamed MT, Wolbink GJ, Rispens T.

Clin Exp Rheumatol. 2019 Aug 30. [Epub ahead of print]

PMID:
31498069
4.

Response to: 'Tapering without relapse in rheumatoid arthritis patients with high TNF blocker concentrations: data from the STRASS study' by Marotte et al.

l'Ami MJ, Krieckaert CL, Nurmohamed MT, van Vollenhoven RF, Rispens T, Boers M, Wolbink GJ.

Ann Rheum Dis. 2019 May 9. pii: annrheumdis-2019-215609. doi: 10.1136/annrheumdis-2019-215609. [Epub ahead of print] No abstract available.

PMID:
31072816
5.

Serum drug concentrations to optimize switching from adalimumab to etanercept in rheumatoid arthritis.

L' Ami MJ, Ruwaard J, Krieckaert C, Nurmohamed MT, van Vollenhoven RF, Rispens T, Wolbink GJ.

Scand J Rheumatol. 2019 Jul;48(4):266-270. doi: 10.1080/03009742.2019.1577915. Epub 2019 Apr 23.

PMID:
31012365
6.

Association between concomitant csDMARDs and clinical response to TNF inhibitors in overweight patients with axial spondyloarthritis.

Hernández-Breijo B, Plasencia-Rodríguez C, Navarro-Compán V, Martínez-Feito A, Jochems A, Kneepkens EL, Wolbink GJ, Rispens T, Diego C, Pascual-Salcedo D, Balsa A.

Arthritis Res Ther. 2019 Feb 20;21(1):66. doi: 10.1186/s13075-019-1849-3.

7.

Dynamics of circulating TNF during adalimumab treatment using a drug-tolerant TNF assay.

Berkhout LC, l'Ami MJ, Ruwaard J, Hart MH, Heer PO, Bloem K, Nurmohamed MT, van Vollenhoven RF, Boers M, Alvarez DF, Smith CH, Wolbink GJ, Rispens T.

Sci Transl Med. 2019 Jan 30;11(477). pii: eaat3356. doi: 10.1126/scitranslmed.aat3356.

PMID:
30700574
8.

Capillary blood microsampling to determine serum biopharmaceutical concentration: Mitra® microsampler vs dried blood spot.

Bloem K, Schaap T, Boshuizen R, Kneepkens EL, Wolbink GJ, Vries A, Rispens T.

Bioanalysis. 2018 Jun 1;10(11):815-823. doi: 10.4155/bio-2018-0010. Epub 2018 Jun 4.

PMID:
29863412
9.

Response to: Comment on l'Ami et al titled 'Successful reduction of overexposure in patients with rheumatoid arthritis with high serum adalimumab concentrations: an open-label, non-inferiority, randomised clinical trial' by den Broeder et al.

l'Ami MJ, Krieckaert CLM, Nurmohamed MT, van Vollenhoven RF, Rispens T, Boers M, Wolbink GJ.

Ann Rheum Dis. 2018 Oct;77(10):e68. doi: 10.1136/annrheumdis-2017-212602. Epub 2017 Nov 13. No abstract available.

PMID:
29133475
10.

Optimal concentration range of golimumab in patients with axial spondyloarthritis.

Martínez-Feito A, Plasencia-Rodriguez C, Navarro-Compán V, Jurado T, Kneepkens EL, Wolbink GJ, Martín S, Ruiz Del Agua A, Navarro R, Mezcua A, Jochems A, Peiteado D, Bonilla MG, Balsa A, Pascual-Salcedo D.

Clin Exp Rheumatol. 2018 Jan-Feb;36(1):110-114. Epub 2017 Sep 15.

PMID:
28980904
11.

Successful reduction of overexposure in patients with rheumatoid arthritis with high serum adalimumab concentrations: an open-label, non-inferiority, randomised clinical trial.

l'Ami MJ, Krieckaert CL, Nurmohamed MT, van Vollenhoven RF, Rispens T, Boers M, Wolbink GJ.

Ann Rheum Dis. 2018 Apr;77(4):484-487. doi: 10.1136/annrheumdis-2017-211781. Epub 2017 Sep 22.

PMID:
28939629
12.

Dried blood spots from finger prick facilitate therapeutic drug monitoring of adalimumab and anti-adalimumab in patients with inflammatory diseases.

Kneepkens EL, Pouw MF, Wolbink GJ, Schaap T, Nurmohamed MT, de Vries A, Rispens T, Bloem K.

Br J Clin Pharmacol. 2017 Nov;83(11):2474-2484. doi: 10.1111/bcp.13371. Epub 2017 Aug 22.

13.

Infusion reactions during infliximab treatment are not associated with IgE anti-infliximab antibodies.

van Schie KA, Ooijevaar-De Heer P, Kruithof S, Plasencia C, Jurado T, Pascual Salcedo D, Brandse JF, d'Haens GR, Wolbink GJ, Rispens T.

Ann Rheum Dis. 2017 Jul;76(7):1285-1288. doi: 10.1136/annrheumdis-2016-211035. Epub 2017 Apr 28.

PMID:
28455438
14.

Long-term treatment response in rheumatoid arthritis patients starting adalimumab or etanercept with or without concomitant methotrexate.

l'Ami MJ, Kneepkens EL, Nurmohamed MT, Krieckaert CLM, Visman IM, Wolbink GJ.

Clin Exp Rheumatol. 2017 May-Jun;35(3):431-437. Epub 2017 Jan 5.

PMID:
28079512
15.

Brief Report: The Role of Rare Protein-Coding Variants in Anti-Tumor Necrosis Factor Treatment Response in Rheumatoid Arthritis.

Cui J, Diogo D, Stahl EA, Canhao H, Mariette X, Greenberg JD, Okada Y, Pappas DA, Fulton RS, Tak PP, Nurmohamed MT, Lee A, Larson DE, Kurreeman F, Deluca TL, O'Laughlin M, Fronick CC, Fulton LL, Mardis ER, van der Horst-Bruinsma IE, Wolbink GJ, Gregersen PK, Kremer JM, Crusius JB, de Vries N, Huizinga TW, Fonseca JE, Miceli-Richard C, Karlson EW, Coenen MJ, Barton A, Plenge RM, Raychaudhuri S.

Arthritis Rheumatol. 2017 Apr;69(4):735-741. doi: 10.1002/art.39966.

16.

Cross-reactive and pre-existing antibodies to therapeutic antibodies--Effects on treatment and immunogenicity.

van Schie KA, Wolbink GJ, Rispens T.

MAbs. 2015;7(4):662-71. doi: 10.1080/19420862.2015.1048411. Review.

17.

Crossreactivity to vinculin and microbes provides a molecular basis for HLA-based protection against rheumatoid arthritis.

van Heemst J, Jansen DT, Polydorides S, Moustakas AK, Bax M, Feitsma AL, Bontrop-Elferink DG, Baarse M, van der Woude D, Wolbink GJ, Rispens T, Koning F, de Vries RR, Papadopoulos GK, Archontis G, Huizinga TW, Toes RE.

Nat Commun. 2015 May 5;6:6681. doi: 10.1038/ncomms7681.

PMID:
25942574
18.

The correlation of clinical efficacy, serum trough levels and antidrug antibodies in ustekinumab-treated patients with psoriasis in a clinical-practice setting.

Menting SP, van den Reek JM, Baerveldt EM, de Jong EM, Prens EP, Lecluse LL, Wolbink GJ, Van der Kleij D, Spuls PI, Rispens T.

Br J Dermatol. 2015 Sep;173(3):855-7. doi: 10.1111/bjd.13834. Epub 2015 Aug 2. No abstract available.

PMID:
25865153
19.

Response to: 'The antibody response against human and chimeric anti-TNF therapeutic antibodies primarily targets the TNF binding region' by Rinaudo-Gaujous et al.

van Schie KA, Hart MH, de Groot ER, Kruithof S, Aarden LA, Wolbink GJ, Rispens T.

Ann Rheum Dis. 2015 Aug;74(8):e41. doi: 10.1136/annrheumdis-2015-207529. Epub 2015 Apr 8. No abstract available.

PMID:
25854585
20.

Systematic comparison of drug-tolerant assays for anti-drug antibodies in a cohort of adalimumab-treated rheumatoid arthritis patients.

Bloem K, van Leeuwen A, Verbeek G, Nurmohamed MT, Wolbink GJ, van der Kleij D, Rispens T.

J Immunol Methods. 2015 Mar;418:29-38. doi: 10.1016/j.jim.2015.01.007. Epub 2015 Jan 27.

PMID:
25637408
21.

Adalimumab trough concentrations in patients with rheumatoid arthritis and psoriatic arthritis treated with concomitant disease-modifying antirheumatic drugs.

Vogelzang EH, Pouw MF, Nurmohamed M, Kneepkens EL, Rispens T, Wolbink GJ, Krieckaert CL.

Ann Rheum Dis. 2015 Feb;74(2):474-5. doi: 10.1136/annrheumdis-2014-206588. Epub 2014 Nov 28. No abstract available.

PMID:
25433018
22.

The antibody response against human and chimeric anti-TNF therapeutic antibodies primarily targets the TNF binding region.

van Schie KA, Hart MH, de Groot ER, Kruithof S, Aarden LA, Wolbink GJ, Rispens T.

Ann Rheum Dis. 2015 Jan;74(1):311-4. doi: 10.1136/annrheumdis-2014-206237. Epub 2014 Oct 23.

PMID:
25342759
23.

Lower etanercept levels are associated with high disease activity in ankylosing spondylitis patients at 24 weeks of follow-up.

Kneepkens EL, Krieckaert CL, van der Kleij D, Nurmohamed MT, van der Horst-Bruinsma IE, Rispens T, Wolbink GJ.

Ann Rheum Dis. 2015 Oct;74(10):1825-9. doi: 10.1136/annrheumdis-2014-205213. Epub 2014 May 7.

PMID:
24812290
24.

A genome-wide association study of rheumatoid arthritis without antibodies against citrullinated peptides.

Bossini-Castillo L, de Kovel C, Kallberg H, van 't Slot R, Italiaander A, Coenen M, Tak PP, Posthumus MD, Wijmenga C, Huizinga T, van der Helm-van Mil AH, Stoeken-Rijsbergen G, Rodriguez-Rodriguez L, Balsa A, González-Álvaro I, González-Gay MÁ, Gómez-Vaquero C, Franke B; LifeLines Cohort Study, Vermeulen S, van der Horst-Bruinsma Ie, Dijkmans BA, Wolbink GJ, Ophoff RA, Maehlen MT, van Riel P, Merriman M, Klareskog L, Lie BA, Merriman T, Crusius JB, Brouwer E, Martin J, de Vries N, Toes R, Padyukov L, Koeleman BP.

Ann Rheum Dis. 2015 Mar;74(3):e15. doi: 10.1136/annrheumdis-2013-204591. Epub 2014 Feb 14.

PMID:
24532677
25.

Drug interference in immunogenicity assays depends on valency.

Rispens T, Hart MH, Ooijevaar-de Heer P, van Leeuwen A, Vennegoor A, Killestein J, Wolbink GJ, van der Kleij D.

J Pharm Biomed Anal. 2013 Nov;85:179-85. doi: 10.1016/j.jpba.2013.07.022. Epub 2013 Jul 30.

PMID:
23954437
26.

Methotrexate normalizes up-regulated folate pathway genes in rheumatoid arthritis.

Blits M, Jansen G, Assaraf YG, van de Wiel MA, Lems WF, Nurmohamed MT, van Schaardenburg D, Voskuyl AE, Wolbink GJ, Vosslamber S, Verweij CL.

Arthritis Rheum. 2013 Nov;65(11):2791-802. doi: 10.1002/art.38094.

27.

Drug levels, anti-drug antibodies, and clinical efficacy of the anti-TNFα biologics in rheumatic diseases.

Mok CC, van der Kleij D, Wolbink GJ.

Clin Rheumatol. 2013 Oct;32(10):1429-35. doi: 10.1007/s10067-013-2336-x. Epub 2013 Jul 26.

PMID:
23887439
28.

A rapid assay for on-site monitoring of infliximab trough levels: a feasibility study.

Corstjens PL, Fidder HH, Wiesmeijer KC, de Dood CJ, Rispens T, Wolbink GJ, Hommes DW, Tanke HJ.

Anal Bioanal Chem. 2013 Sep;405(23):7367-75. doi: 10.1007/s00216-013-7154-0. Epub 2013 Jul 9.

PMID:
23836086
29.

The minipig as an alternative non-rodent model for immunogenicity testing using the TNFα blockers adalimumab and infliximab.

van Mierlo GJ, Cnubben NH, Wouters D, Wolbink GJ, Hart MH, Rispens T, Ganderup NC, Kuper CF, Aarden L, Penninks AH.

J Immunotoxicol. 2014 Jan-Mar;11(1):62-71. doi: 10.3109/1547691X.2013.796023. Epub 2013 Jun 5.

PMID:
23738746
30.

The combined use of disease activity and infliximab serum trough concentrations for early prediction of (non-)response to infliximab in rheumatoid arthritis.

van den Bemt BJ, den Broeder AA, Wolbink GJ, van den Maas A, Hekster YA, van Riel PL, Benraad HB, van den Hoogen FH.

Br J Clin Pharmacol. 2013 Dec;76(6):939-45. doi: 10.1111/bcp.12142.

31.

Genome-wide association study and gene expression analysis identifies CD84 as a predictor of response to etanercept therapy in rheumatoid arthritis.

Cui J, Stahl EA, Saevarsdottir S, Miceli C, Diogo D, Trynka G, Raj T, Mirkov MU, Canhao H, Ikari K, Terao C, Okada Y, Wedrén S, Askling J, Yamanaka H, Momohara S, Taniguchi A, Ohmura K, Matsuda F, Mimori T, Gupta N, Kuchroo M, Morgan AW, Isaacs JD, Wilson AG, Hyrich KL, Herenius M, Doorenspleet ME, Tak PP, Crusius JB, van der Horst-Bruinsma IE, Wolbink GJ, van Riel PL, van de Laar M, Guchelaar HJ, Shadick NA, Allaart CF, Huizinga TW, Toes RE, Kimberly RP, Bridges SL Jr, Criswell LA, Moreland LW, Fonseca JE, de Vries N, Stranger BE, De Jager PL, Raychaudhuri S, Weinblatt ME, Gregersen PK, Mariette X, Barton A, Padyukov L, Coenen MJ, Karlson EW, Plenge RM.

PLoS Genet. 2013 Mar;9(3):e1003394. doi: 10.1371/journal.pgen.1003394. Epub 2013 Mar 28.

32.

Immunogenicity of anti-TNF biologic therapies for rheumatoid arthritis.

van Schouwenburg PA, Rispens T, Wolbink GJ.

Nat Rev Rheumatol. 2013 Mar;9(3):164-72. doi: 10.1038/nrrheum.2013.4. Epub 2013 Feb 12. Review.

PMID:
23399692
33.

Long-term measurement of anti-adalimumab using pH-shift-anti-idiotype antigen binding test shows predictive value and transient antibody formation.

van Schouwenburg PA, Krieckaert CL, Rispens T, Aarden L, Wolbink GJ, Wouters D.

Ann Rheum Dis. 2013 Oct;72(10):1680-6. doi: 10.1136/annrheumdis-2012-202407. Epub 2013 Jan 7.

PMID:
23300118
34.

Adalimumab elicits a restricted anti-idiotypic antibody response in autoimmune patients resulting in functional neutralisation.

van Schouwenburg PA, van de Stadt LA, de Jong RN, van Buren EE, Kruithof S, de Groot E, Hart M, van Ham SM, Rispens T, Aarden L, Wolbink GJ, Wouters D.

Ann Rheum Dis. 2013 Jan;72(1):104-9. doi: 10.1136/annrheumdis-2012-201445. Epub 2012 Jul 3.

PMID:
22759910
35.

IgG4 production against adalimumab during long term treatment of RA patients.

van Schouwenburg PA, Krieckaert CL, Nurmohamed M, Hart M, Rispens T, Aarden L, Wouters D, Wolbink GJ.

J Clin Immunol. 2012 Oct;32(5):1000-6. doi: 10.1007/s10875-012-9705-0. Epub 2012 May 24.

PMID:
22622790
36.

Methotrexate reduces immunogenicity in adalimumab treated rheumatoid arthritis patients in a dose dependent manner.

Krieckaert CL, Nurmohamed MT, Wolbink GJ.

Ann Rheum Dis. 2012 Nov;71(11):1914-5. doi: 10.1136/annrheumdis-2012-201544. Epub 2012 May 14. No abstract available.

PMID:
22586169
37.

Natalizumab remains detectable in patients with multiple sclerosis long after treatment is stopped.

Rispens T, Vennegoor A, Wolbink GJ, Polman CH, Killestein J.

Mult Scler. 2012 Jun;18(6):899-901. doi: 10.1177/1352458511431073. Epub 2011 Dec 19.

PMID:
22183929
38.

Antibodies to constant domains of therapeutic monoclonal antibodies: anti-hinge antibodies in immunogenicity testing.

Rispens T, de Vrieze H, de Groot E, Wouters D, Stapel S, Wolbink GJ, Aarden LA.

J Immunol Methods. 2012 Jan 31;375(1-2):93-9. doi: 10.1016/j.jim.2011.09.011. Epub 2011 Oct 1.

PMID:
21986105
39.

Patients non-responding to etanercept obtain lower etanercept concentrations compared with responding patients.

Jamnitski A, Krieckaert CL, Nurmohamed MT, Hart MH, Dijkmans BA, Aarden L, Voskuyl AE, Wolbink GJ.

Ann Rheum Dis. 2012 Jan;71(1):88-91. doi: 10.1136/annrheumdis-2011-200184. Epub 2011 Sep 12.

PMID:
21914626
40.

Differential effect of drug interference in immunogenicity assays.

Hart MH, de Vrieze H, Wouters D, Wolbink GJ, Killestein J, de Groot ER, Aarden LA, Rispens T.

J Immunol Methods. 2011 Sep 30;372(1-2):196-203. doi: 10.1016/j.jim.2011.07.019. Epub 2011 Jul 29.

PMID:
21824477
41.

Development of antidrug antibodies against adalimumab and association with disease activity and treatment failure during long-term follow-up.

Bartelds GM, Krieckaert CL, Nurmohamed MT, van Schouwenburg PA, Lems WF, Twisk JW, Dijkmans BA, Aarden L, Wolbink GJ.

JAMA. 2011 Apr 13;305(14):1460-8. doi: 10.1001/jama.2011.406.

PMID:
21486979
42.

Venous and arterial thromboembolic events in adalimumab-treated patients with antiadalimumab antibodies: a case series and cohort study.

Korswagen LA, Bartelds GM, Krieckaert CL, Turkstra F, Nurmohamed MT, van Schaardenburg D, Wijbrandts CA, Tak PP, Lems WF, Dijkmans BA, van Vugt RM, Wolbink GJ.

Arthritis Rheum. 2011 Apr;63(4):877-83. doi: 10.1002/art.30209.

43.

Comparison of analytical methods to detect instability of etanercept during thermal stress testing.

Maarschalkerweerd Av, Wolbink GJ, Stapel SO, Jiskoot W, Hawe A.

Eur J Pharm Biopharm. 2011 Jun;78(2):213-21. doi: 10.1016/j.ejpb.2011.01.012. Epub 2011 Jan 24.

PMID:
21272639
44.

Anti-infliximab antibodies are already detectable in most patients with rheumatoid arthritis halfway through an infusion cycle: an open-label pharmacokinetic cohort study.

van den Bemt BJ, den Broeder AA, Wolbink GJ, Hekster YA, van Riel PL, Benraad B, van den Hoogen FH.

BMC Musculoskelet Disord. 2011 Jan 13;12:12. doi: 10.1186/1471-2474-12-12.

45.

Measurement of serum levels of natalizumab, an immunoglobulin G4 therapeutic monoclonal antibody.

Rispens T, Leeuwen Av, Vennegoor A, Killestein J, Aalberse RC, Wolbink GJ, Aarden LA.

Anal Biochem. 2011 Apr 15;411(2):271-6. doi: 10.1016/j.ab.2011.01.001. Epub 2011 Jan 7.

PMID:
21216215
46.

Surprising negative association between IgG1 allotype disparity and anti-adalimumab formation: a cohort study.

Bartelds GM, de Groot E, Nurmohamed MT, Hart MH, van Eede PH, Wijbrandts CA, Crusius JB, Dijkmans BA, Tak PP, Aarden L, Wolbink GJ.

Arthritis Res Ther. 2010;12(6):R221. doi: 10.1186/ar3208. Epub 2010 Dec 27.

47.

The presence or absence of antibodies to infliximab or adalimumab determines the outcome of switching to etanercept.

Jamnitski A, Bartelds GM, Nurmohamed MT, van Schouwenburg PA, van Schaardenburg D, Stapel SO, Dijkmans BA, Aarden L, Wolbink GJ.

Ann Rheum Dis. 2011 Feb;70(2):284-8. doi: 10.1136/ard.2010.135111. Epub 2010 Nov 10.

PMID:
21068090
48.

The extent of the anti-citrullinated protein antibody repertoire is associated with arthritis development in patients with seropositive arthralgia.

van de Stadt LA, van der Horst AR, de Koning MH, Bos WH, Wolbink GJ, van de Stadt RJ, Pruijn GJ, Dijkmans BA, van Schaardenburg D, Hamann D.

Ann Rheum Dis. 2011 Jan;70(1):128-33. doi: 10.1136/ard.2010.132662. Epub 2010 Nov 9.

PMID:
21062853
49.

The effect of immunomodulators on the immunogenicity of TNF-blocking therapeutic monoclonal antibodies: a review.

Krieckaert CL, Bartelds GM, Lems WF, Wolbink GJ.

Arthritis Res Ther. 2010;12(5):217. doi: 10.1186/ar3147. Epub 2010 Oct 20. Review.

50.

Therapy: Immunogenicity of biologic therapies-we need tolerance.

Krieckaert CL, Bartelds GM, Wolbink GJ.

Nat Rev Rheumatol. 2010 Oct;6(10):558-9. doi: 10.1038/nrrheum.2010.153. No abstract available.

PMID:
20882023

Supplemental Content

Loading ...
Support Center